376 related articles for article (PubMed ID: 33188876)
1. Designing precision medicine panels for drug refractory cancers targeting cancer stemness traits.
Warrier S; Patil M; Bhansali S; Varier L; Sethi G
Biochim Biophys Acta Rev Cancer; 2021 Jan; 1875(1):188475. PubMed ID: 33188876
[TBL] [Abstract][Full Text] [Related]
2. Stem cell programs in cancer initiation, progression, and therapy resistance.
Huang T; Song X; Xu D; Tiek D; Goenka A; Wu B; Sastry N; Hu B; Cheng SY
Theranostics; 2020; 10(19):8721-8743. PubMed ID: 32754274
[TBL] [Abstract][Full Text] [Related]
3. Emerging functional markers for cancer stem cell-based therapies: Understanding signaling networks for targeting metastasis.
Marquardt S; Solanki M; Spitschak A; Vera J; Pützer BM
Semin Cancer Biol; 2018 Dec; 53():90-109. PubMed ID: 29966677
[TBL] [Abstract][Full Text] [Related]
4. Cancer stem cells (CSCs) in cancer progression and therapy.
Najafi M; Farhood B; Mortezaee K
J Cell Physiol; 2019 Jun; 234(6):8381-8395. PubMed ID: 30417375
[TBL] [Abstract][Full Text] [Related]
5. Cancer stem cell (CSC) resistance drivers.
Najafi M; Mortezaee K; Majidpoor J
Life Sci; 2019 Oct; 234():116781. PubMed ID: 31430455
[TBL] [Abstract][Full Text] [Related]
6. Cancer Stem Cells-Origins and Biomarkers: Perspectives for Targeted Personalized Therapies.
Walcher L; Kistenmacher AK; Suo H; Kitte R; Dluczek S; Strauß A; Blaudszun AR; Yevsa T; Fricke S; Kossatz-Boehlert U
Front Immunol; 2020; 11():1280. PubMed ID: 32849491
[TBL] [Abstract][Full Text] [Related]
7. Advances in Therapeutic Targeting of Cancer Stem Cells within the Tumor Microenvironment: An Updated Review.
Dzobo K; Senthebane DA; Ganz C; Thomford NE; Wonkam A; Dandara C
Cells; 2020 Aug; 9(8):. PubMed ID: 32823711
[TBL] [Abstract][Full Text] [Related]
8. Concise Review: Emerging Role of CD44 in Cancer Stem Cells: A Promising Biomarker and Therapeutic Target.
Yan Y; Zuo X; Wei D
Stem Cells Transl Med; 2015 Sep; 4(9):1033-43. PubMed ID: 26136504
[TBL] [Abstract][Full Text] [Related]
9. Targeting signal transduction pathways of cancer stem cells for therapeutic opportunities of metastasis.
Iqbal W; Alkarim S; AlHejin A; Mukhtar H; Saini KS
Oncotarget; 2016 Nov; 7(46):76337-76353. PubMed ID: 27486983
[TBL] [Abstract][Full Text] [Related]
10. Evolving Strategies for Therapeutically Targeting Cancer Stem Cells.
Talukdar S; Emdad L; Das SK; Sarkar D; Fisher PB
Adv Cancer Res; 2016; 131():159-91. PubMed ID: 27451127
[TBL] [Abstract][Full Text] [Related]
11. Cancer Stem Cells: Acquisition, Characteristics, Therapeutic Implications, Targeting Strategies and Future Prospects.
Yadav AK; Desai NS
Stem Cell Rev Rep; 2019 Jun; 15(3):331-355. PubMed ID: 30993589
[TBL] [Abstract][Full Text] [Related]
12. Antrodia cinnamomea sensitizes radio-/chemo-therapy of cancer stem-like cells by modulating microRNA expression.
Su YK; Shih PH; Lee WH; Bamodu OA; Wu ATH; Huang CC; Tzeng YM; Hsiao M; Yeh CT; Lin CM
J Ethnopharmacol; 2017 Jul; 207():47-56. PubMed ID: 28602756
[TBL] [Abstract][Full Text] [Related]
13. Cancer stem cell targeting: the next generation of cancer therapy and molecular imaging.
Shigdar S; Lin J; Li Y; Yang CJ; Wei M; Zhus Y; Liu H; Duan W
Ther Deliv; 2012 Feb; 3(2):227-44. PubMed ID: 22834199
[TBL] [Abstract][Full Text] [Related]
14. Targeting signalling pathways and the immune microenvironment of cancer stem cells - a clinical update.
Clara JA; Monge C; Yang Y; Takebe N
Nat Rev Clin Oncol; 2020 Apr; 17(4):204-232. PubMed ID: 31792354
[TBL] [Abstract][Full Text] [Related]
15. SOX2 in cancer stemness: tumor malignancy and therapeutic potentials.
Mamun MA; Mannoor K; Cao J; Qadri F; Song X
J Mol Cell Biol; 2020 Feb; 12(2):85-98. PubMed ID: 30517668
[TBL] [Abstract][Full Text] [Related]
16. Insights into new mechanisms and models of cancer stem cell multidrug resistance.
Garcia-Mayea Y; Mir C; Masson F; Paciucci R; LLeonart ME
Semin Cancer Biol; 2020 Feb; 60():166-180. PubMed ID: 31369817
[TBL] [Abstract][Full Text] [Related]
17. The bad seed: Cancer stem cells in tumor development and resistance.
Koren E; Fuchs Y
Drug Resist Updat; 2016 Sep; 28():1-12. PubMed ID: 27620951
[TBL] [Abstract][Full Text] [Related]
18. Novel antibody reagents for characterization of drug- and tumor microenvironment-induced changes in epithelial-mesenchymal transition and cancer stem cells.
Navas T; Pfister TD; Colantonio S; Aziz A; Dieckman L; Saul RG; Kaczmarczyk J; Borgel S; Alcoser SY; Hollingshead MG; Lee YH; Bottaro DP; Hiltke T; Whiteley G; Takebe N; Kinders RJ; Parchment RE; Tomaszewski JE; Doroshow JH
PLoS One; 2018; 13(6):e0199361. PubMed ID: 29928062
[TBL] [Abstract][Full Text] [Related]
19. Cancer cells stemness: A doorstep to targeted therapy.
Prasad S; Ramachandran S; Gupta N; Kaushik I; Srivastava SK
Biochim Biophys Acta Mol Basis Dis; 2020 Apr; 1866(4):165424. PubMed ID: 30818002
[TBL] [Abstract][Full Text] [Related]
20. Regulation and signaling pathways in cancer stem cells: implications for targeted therapy for cancer.
Zeng Z; Fu M; Hu Y; Wei Y; Wei X; Luo M
Mol Cancer; 2023 Oct; 22(1):172. PubMed ID: 37853437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
